Paradigm Biopharma - Bolstering the iPPS data package for OA
Paradigm is focused on the development of injectable pentosan polysulfate (iPPS) for the treatment of osteoarthritis (OA). While the company has...
191 Views
Paradigm Biopharma - Active pipeline and catalysts ahead
Paradigm has shared its March 2023 quarterly update. In Q323, net cash outflow from operating activities was A$10.3m (A$28.1m for the first nine...
150 Views
Paradigm Biopharma - Potential for disease-modifying kOA treatment
Paradigm has announced day 168 (six-month) data from the PARA_OA_008 trial, which is evaluating injectable pentosan polysulfate sodium (iPPS) as a...
349 Views
Paradigm Biopharma - Active year ahead with significant catalysts
Paradigm has presented its half yearly results and accounts, reflecting an active period. This included an encouraging safety review for injectable...
190 Views
Paradigm Biopharma - Funded past near-term inflection points
Cash flow figures from Paradigm Biopharmaceuticals’ latest update show that it remains funded past key near-term inflection points. In Q223,...
225 Views